GSK Stock Forecast for 2022 - 2025 - 2030

Updated on 14.08.2022

Stock Rating
16
Price Target
£19,50
Consensus
Outperform
Upside
34,48%
Analysts
15
Stock Rating
16
Upside
34,48%
Analysts
15
Price Target
£19,50

The average price target of £19,50 for GSK's stock set by fiveteen distinguished analysts in recent weeks would represent a potential upside of approximately 34,48% from the last closing price in August, 2022 if reached by the end of the year. This potential increase is based on a high estimate of £35,93 and a low estimate of £15,40. If you are not interested in GSK stock, you may be interested in its competitors.

£19,50

34,48% Upside

Outperform
Outperform

GSK Fair Value Forecast for 2022 - 2025 - 2030

GSK's Price has decreased In the last three years, from £15,21 to £14,50 – a 4,70% drop. In the next year, analysts believe that Fair Value will reach £15,12 – an increase of 4,29%. For the next nine years, the forecast is for Fair Value to grow by 39,53%.

2022 Fair Value Forecast
£15,12
2023 Fair Value Forecast
£15,78
2024 Fair Value Forecast
£16,33
2025 Fair Value Forecast
£16,97
2026 Fair Value Forecast
£17,60
2027 Fair Value Forecast
£18,23
2028 Fair Value Forecast
£18,89
2029 Fair Value Forecast
£19,56
2030 Fair Value Forecast
£20,23
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
ABBV Stock Forecast AbbVie Outperform 9
$142,60 $164,23 12,20% 19
AZN Stock Forecast AstraZeneca PLC Outperform 18
£107,12 £136,08 36,01% 13
ABT Stock Forecast Abbott Laboratories Outperform 14
$111,48 $128,88 13,02% 19
BMY Stock Forecast Bristol-Myers Squibb Outperform 2
$75,57 $79,05 9,17% 16
AMGN Stock Forecast Amgen Hold 9
$248,39 $246,51 2,66% 13

GSK Revenue Forecast for 2022 - 2025 - 2030

In the last three years, GSK's Revenue has grown, rising from £30,82B to £34,11B – a growth of 10,68%. In the next year, analysts believe that Revenue will reach £35,22B – an increase of 3,25%. For the next nine years, the forecast is for Revenue to grow by 17,79%.

2022 Rev Forecast
£35,22B
2023 Rev Forecast
£35,71B
2024 Rev Forecast
£36,26B
2025 Rev Forecast
£36,98B
2026 Rev Forecast
£37,58B
2027 Rev Forecast
£38,22B
2028 Rev Forecast
£38,88B
2029 Rev Forecast
£39,52B
2030 Rev Forecast
£40,18B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
CSL Stock Forecast CSL Outperform 16
$292,85 $228,01 -23,72% 6
MMM Stock Forecast 3M Hold 16
$152,24 $188,41 -4,76% 17
GILD Stock Forecast Gilead Sciences Outperform 11
$62,96 $69,65 11,18% 19

GSK Dividend per Share Forecast for 2022 - 2025 - 2030

In the last three years, GSK's Dividend per Share has seen a drop from £1,00 to £1,00 – a 0,00% decrease. According to 0 major analysts, GSK's Dividend per Share will fall by 0,00% in the next year, reaching £1,00. Professionals believe that By 2030, GSK's Dividend per Share will fall to £1,00– a 0,00% decrease from its current value.

2022 DPS Forecast
£1,00
2023 DPS Forecast
£1,00
2024 DPS Forecast
£1,00
2025 DPS Forecast
£1,00
2026 DPS Forecast
£1,00
2027 DPS Forecast
£1,00
2028 DPS Forecast
£1,00
2029 DPS Forecast
£1,00
2030 DPS Forecast
£1,00
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BDX Stock Forecast Becton, Dickinson and Outperform 17
$263,69 $274,67 5,81% 3
CL Stock Forecast Colgate-Palmolive Outperform 18
$80,29 $84,90 2,13% 9
BAYN Stock Forecast Bayer Outperform 7
54,15€ 67,79€ 42,20% 14

GSK Free Cash Flow Forecast for 2022 - 2025 - 2030

In the last three years, GSK's Free Cash Flow has fallen from £7,08B to £6,78B – a 4,20% decrease. For the next year, analysts predict that Free Cash Flow will reach £7,15B – an increase of 5,49%. Over the next nine years, experts believe that GSK's Free Cash Flow will grow at a rate of 57,16%.

2022 FCF Forecast
£7,15B
2023 FCF Forecast
£7,56B
2024 FCF Forecast
£7,97B
2025 FCF Forecast
£8,39B
2026 FCF Forecast
£8,82B
2027 FCF Forecast
£9,26B
2028 FCF Forecast
£9,72B
2029 FCF Forecast
£10,18B
2030 FCF Forecast
£10,66B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥3,68k ¥0,00 14,22% 0
ADM Stock Forecast Archer-Daniels-Midland Outperform 11
$86,60 $95,08 9,70% 3
4519 Stock Forecast Chugai Pharmaceutical Hold 18
¥3,86k ¥0,00 16,55% 0

GSK Net Income Forecast for 2022 - 2025 - 2030

GSK's Net Income has seen impressive growth In the last three years, rising from £3,62B to £4,39B – a growth of 21,03%. In the next year, analysts believe that Net Income will reach £5,44B – an increase of 24,10%. For the next nine years, the forecast is for Net Income to grow by 359,08%.

2022 NI Forecast
£5,44B
2023 NI Forecast
£6,71B
2024 NI Forecast
£8,26B
2025 NI Forecast
£9,83B
2026 NI Forecast
£11,59B
2027 NI Forecast
£13,51B
2028 NI Forecast
£15,56B
2029 NI Forecast
£17,77B
2030 NI Forecast
£20,13B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
ABEV3 Stock Forecast Ambev Outperform 18
R$15,21 R$17,64 15,06% 3
CTVA Stock Forecast Corteva Outperform 12
$61,76 $62,59 8,48% 13
A Stock Forecast Agilent Technologies Outperform 17
$133,55 $144,80 8,57% 2

GSK EBITDA Forecast for 2022 - 2025 - 2030

In the last three years, GSK's EBITDA has grown, moving from £9,35B to £9,91B – an increase of 5,92%. In the next year, analysts predict that EBITDA will jump to £10,35B – up 4,53% from the current level. Looking ahead to nine years, experts forecast that EBITDA will grow by 35,89%.

2022 EBITDA Forecast
£10,35B
2023 EBITDA Forecast
£10,65B
2024 EBITDA Forecast
£11,05B
2025 EBITDA Forecast
£11,45B
2026 EBITDA Forecast
£11,82B
2027 EBITDA Forecast
£12,23B
2028 EBITDA Forecast
£12,63B
2029 EBITDA Forecast
£13,04B
2030 EBITDA Forecast
£13,46B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
BN Stock Forecast Danone Hold 18
52,70€ 62,59€ 10,06% 18
ALC Stock Forecast Alcon Outperform 15
CHF65,48 CHF0,00 28,77% 6
HEN3 Stock Forecast Henkel AG & Co. KGaA Hold 16
64,78€ 95,86€ 3,43% 17

GSK EBIT Forecast for 2022 - 2025 - 2030

In the last three years, GSK's EBIT has seen an increase, rising from £7,50B to £7,97B. This represents a growth of 6,28%. Analysts predict that GSK's EBIT will increase in the upcoming year, reaching £8,42B. This would represent an increase of 5,76%. Over the next nine years, experts predict that GSK's EBIT will grow at a rate of 53,25%.

2022 EBIT Forecast
£8,42B
2023 EBIT Forecast
£8,82B
2024 EBIT Forecast
£9,29B
2025 EBIT Forecast
£9,75B
2026 EBIT Forecast
£10,21B
2027 EBIT Forecast
£10,70B
2028 EBIT Forecast
£11,19B
2029 EBIT Forecast
£11,69B
2030 EBIT Forecast
£12,21B
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
4503 Stock Forecast Astellas Pharma Outperform 18
¥2,03k ¥0,00 17,97% 0
COLO B Stock Forecast Coloplast A/S Hold 18
kr839,60 kr1,05k 22,68% 13
BEI Stock Forecast Beiersdorf Outperform 17
101,75€ 102,71€ 8,11% 13

GSK EPS Price Prediction Forecast for 2022 - 2025 - 2030

GSK's EPS has decreased In the last three years, from £1,49 to £1,42 – a 4,70% drop. In the next year, analysts believe that EPS will reach £1,48 – an increase of 4,29%. For the next nine years, the forecast is for EPS to grow by 39,53%.

2022 EPS Forecast
£1,48
2023 EPS Forecast
£1,55
2024 EPS Forecast
£1,60
2025 EPS Forecast
£1,66
2026 EPS Forecast
£1,72
2027 EPS Forecast
£1,79
2028 EPS Forecast
£1,85
2029 EPS Forecast
£1,92
2030 EPS Forecast
£1,98
Ticker Name Consensus Stock Rating Price Price Target Upside/Downside Analysts
CHD Stock Forecast Church & Dwight Hold 11
$87,70 $88,52 6,04% 9
HOLX Stock Forecast Hologic Outperform 8
$72,99 $77,18 2,75% 12
4523 Stock Forecast Eisai Hold 18
¥6,12k ¥0,00 7,93% 0